BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Olomorasib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Olomorasib\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04956640-2053@assetmemo.bio
DTSTAMP:20261121T004554Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Olomorasib: Phase 1/2 readout est. (NCT04956640)
DESCRIPTION:Olomorasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: St
 udy of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS
  G12C)\nEstimated primary completion: April 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/olomorasib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04956640
URL:https://assetmemo.bio/drug/olomorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06119581-2053@assetmemo.bio
DTSTAMP:20261121T004554Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Olomorasib: Phase 3 readout est. (NCT06119581)
DESCRIPTION:Olomorasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without
  Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lu
 ng Cancer\nEstimated primary completion: November 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/olomorasib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06119581
URL:https://assetmemo.bio/drug/olomorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07814417-2053@assetmemo.bio
DTSTAMP:20261121T004554Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Olomorasib: Phase 2 readout est. (NCT07814417)
DESCRIPTION:Olomorasib\, phase 2.\nStudy: A Study of Olomorasib (LY3537982)
  in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation\
 nEstimated primary completion: November 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/olomorasib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07814417
URL:https://assetmemo.bio/drug/olomorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227025-2053@assetmemo.bio
DTSTAMP:20261121T004554Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Olomorasib: Phase 1/2 readout est. (NCT07227025)
DESCRIPTION:Olomorasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Amivantamab and Olomorasib Combination Therapy in Participants Wi
 th Metastatic Non-Small Cell Lung Cancer\nEstimated primary completion: 30
  November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olomo
 rasib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07227025
URL:https://assetmemo.bio/drug/olomorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06890598-2053@assetmemo.bio
DTSTAMP:20261121T004554Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Olomorasib: Phase 3 readout est. (NCT06890598)
DESCRIPTION:Olomorasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Stud
 y of Olomorasib (LY3537982) in Combination With Standard of Care in Partic
 ipants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung 
 Cancer\nEstimated primary completion: May 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/olomorasib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06890598
URL:https://assetmemo.bio/drug/olomorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890714-2053@assetmemo.bio
DTSTAMP:20261121T004554Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Olomorasib: Phase 1/2 readout est. (NCT07890714)
DESCRIPTION:Olomorasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (T
 P04)]\nEstimated primary completion: 30 September 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/olomorasib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07890714
URL:https://assetmemo.bio/drug/olomorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
